This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
HVTN 503 was a randomized, parallel-design, phase 2 prevention trial in HIV-uninfected South African adults. The trial compared MRKAd5 HIV-1 Gag/Pol/Nef with placebo and registered two primary endpoints: acquisition of HIV-1 infection throughout the study and viral load set point among participants who became HIV infected.
| Feature | HVTN 503 |
|---|---|
| Study acronym | HVTN 503 |
| Phase | Phase 2 |
| Status | Completed |
| Start date | 2007-01 |
| Primary completion date | 2012-08 |
| Population | HIV-uninfected South African adults |
| Condition | HIV Infections |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Prevention |
| Enrollment | 801 |
| Number of arms | 2 |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Sponsor type | NIH |
| ClinicalTrials.gov | NCT00413725 |
2. Clinical Question
The statistical question is whether assignment to a three-dose regimen of MRKAd5 HIV-1 Gag/Pol/Nef affects the occurrence of HIV-1 infection and, among participants who become HIV infected, the subsequent viral load set point measured at approximately 3 months postdiagnosis.
Population
HIV-uninfected South African adults participating in a prevention trial.
Intervention
MRKAd5 HIV-1 gag/pol/nef, a biological intervention administered as a three-dose regimen.
Comparator
Placebo.
Primary question
Does randomized assignment to the vaccine regimen change HIV-1 acquisition and, among participants who become infected, viral load set point?
3. Trial Design
MRKAd5 HIV-1 Gag/Pol/Nef
- Biological intervention
- Three-dose regimen
- Evaluated for prevention of HIV-1 infection
Placebo
- Placebo intervention
- Parallel comparison with the vaccine regimen
- Evaluated against the same registered primary endpoints
4. Registered Primary Endpoints
| Primary endpoint | Registry time frame | Statistical structure |
|---|---|---|
| Acquisition of HIV-1 infection | Throughout study | Occurrence of an infection event over follow-up |
| Viral load set point (HIV-1 RNA) in study participants who become HIV infected | At approximately 3 months postdiagnosis | Continuous virologic outcome measured among participants who become HIV infected |
These endpoints address two different stages of the prevention question. HIV-1 acquisition asks whether infection occurs during study follow-up. Viral load set point asks about the level of HIV-1 RNA among participants who become infected, at approximately 3 months postdiagnosis.
Acquisition endpoint
This is fundamentally a time-to-event question when participants are followed over time. The important statistical features are the time at risk, infection events, and censoring for participants who do not experience the event during observed follow-up.
Viral load set point
This endpoint is evaluated only among study participants who become HIV infected. It therefore represents a conditional analysis within the subset experiencing the infection event, rather than an endpoint observed in every randomized participant.
5. Statistical Methodology
Analysis of HIV-1 acquisition
HIV-1 acquisition is naturally represented as an event occurring during follow-up. A time-to-event analysis can use the time from the relevant trial origin to HIV-1 infection, with participants who remain uninfected contributing information until their last observed follow-up or another prespecified censoring point.
Here, T represents the time to HIV-1 acquisition. The survival function describes the probability of remaining free of the event beyond time t.
For a randomized prevention comparison, Kaplan-Meier estimation can describe the event-free experience over time, while a log-rank comparison can assess separation between randomized groups. A Cox proportional-hazards model can provide a hazard ratio when the proportional-hazards framework is appropriate. The exact statistical model, censoring rules, and inferential procedure should be taken from the prespecified statistical analysis plan when available.
Incidence-rate interpretation
An alternative descriptive representation is an incidence rate based on the number of HIV-1 acquisition events divided by accumulated person-time at risk. This is conceptually different from a risk proportion because it explicitly incorporates the amount of follow-up contributed by participants.
The denominator reflects the total time during which participants remain at risk of HIV-1 acquisition.
For this trial, an incidence-rate comparison and a time-to-event comparison answer related but not identical questions. The former emphasizes event occurrence per unit of person-time, whereas the latter describes how the event-free experience changes over follow-up.
Analysis of viral load set point
Viral load set point is defined as HIV-1 RNA in study participants who become HIV infected, assessed at approximately 3 months postdiagnosis. Because this is a quantitative laboratory measurement, it can be summarized as a continuous outcome and compared between the randomized groups among participants meeting the endpoint definition.
A continuous-outcome analysis might compare group means or medians, depending on the distribution of HIV-1 RNA and the prespecified analysis plan. If an approximately Gaussian analysis is appropriate after a suitable transformation, a difference in means can be used. If the distribution is substantially non-normal, robust or rank-based methods may be more appropriate. The registry information available here does not specify which particular model or transformation was used.
Randomization and causal interpretation
The randomized allocation is especially important for interpreting the acquisition endpoint. Before outcomes are observed, assignment creates the basis for a causal comparison between the intervention and placebo groups. For the viral load endpoint, however, restricting attention to participants who become infected changes the conditioning set. The statistical interpretation therefore requires more care than simply applying the same randomized-group logic to the entire cohort.
Confidence intervals
For either endpoint, an effect estimate is more informative when accompanied by an appropriate confidence interval. A confidence interval expresses statistical uncertainty around the estimated effect under the specified model and sampling framework. It does not describe the range of outcomes that individual participants will experience.
6. Planned Analysis
The ClinicalTrials.gov record lists HIV-1 acquisition throughout the study as a primary endpoint but does not post a formal statistical analysis or numerical result for that endpoint. For an event occurring during follow-up, the usual statistical framework is time-to-event analysis, with the treatment groups compared using an appropriate event-time method and the follow-up and censoring rules defined prospectively.
The second primary endpoint is viral load set point (HIV-1 RNA) in study participants who become HIV infected, measured at approximately 3 months postdiagnosis. A typical analysis would treat viral load as a continuous outcome among participants satisfying the endpoint definition. The appropriate summary and comparison method would depend on the distribution of the measurements and the prespecified analysis plan.
| Endpoint | Typical statistical framework | Key interpretation issue |
|---|---|---|
| Acquisition of HIV-1 infection | Time-to-event methods such as Kaplan-Meier estimation, log-rank comparison, or Cox modeling | Follow-up time and censoring must be handled consistently between randomized groups. |
| Viral load set point (HIV-1 RNA) | Continuous-outcome comparison among participants who become HIV infected | The endpoint is conditional on infection and therefore is not measured in the entire randomized cohort. |
7. Statistical Methods Explained
Why is HIV-1 acquisition naturally a time-to-event endpoint?
Because participants can become infected at different times during follow-up, simply counting infections can discard information about when those infections occurred. A time-to-event framework uses both the occurrence of infection and the amount of follow-up contributed by participants who remain uninfected.
What does censoring mean in an HIV prevention study?
Censoring occurs when a participant's event-free follow-up ends before an HIV-1 acquisition event is observed under the analysis rules. Rather than treating that participant as having experienced no possibility of infection indefinitely, a survival analysis uses the information available up to the censoring time.
Why are HIV acquisition and viral load set point different statistical endpoints?
Acquisition asks whether infection occurs. Viral load set point asks about the level of HIV-1 RNA after infection has occurred. The first endpoint concerns the prevention event itself; the second characterizes virologic status among participants who experienced that event.
Why is the viral load endpoint analyzed in a subset?
The registry defines the endpoint specifically in study participants who become HIV infected. Participants who do not become infected do not have a postdiagnosis viral load set point to analyze. This makes the endpoint structurally different from an outcome observed in every randomized participant.
Why should a subset analysis not automatically be interpreted like an ITT analysis?
Randomization protects the original treatment comparison because assignment occurs before outcomes are known. Once an analysis conditions on a post-randomization event such as becoming infected, the analyzed subset can have different statistical properties from the full randomized population. The resulting estimate therefore requires a more careful causal interpretation.
Why might HIV-1 RNA require transformation or a robust analysis?
Virologic measurements can have distributions that are not well described by an untransformed normal model. A prespecified transformation or a method appropriate for skewed continuous data can improve the validity of the comparison. The available registry record does not specify a particular transformation or model.
8. Interpreting the Two Primary Questions Together
The two registered primary endpoints can be viewed as addressing complementary components of vaccine performance. The first asks about susceptibility to acquisition: does infection occur during the study? The second asks about virologic status after acquisition: among participants who become infected, what is the HIV-1 RNA viral load set point at approximately 3 months postdiagnosis?
Question 1: Prevention
The acquisition endpoint is directly aligned with the trial's primary purpose of prevention. Its natural analysis focuses on the incidence and timing of HIV-1 infection.
Question 2: Virologic outcome
The viral load endpoint examines a post-infection quantitative outcome. It provides a different statistical perspective from the prevention endpoint because it is evaluated only after infection occurs.
Keeping these questions separate is important. A single summary measure cannot simultaneously represent the probability or timing of acquisition and the viral load level among participants who become infected. Each endpoint has its own estimand, analysis population, and interpretation.
9. Analysis Populations and Conditioning
| Population concept | Role in this trial |
|---|---|
| Randomized population | The 801 enrolled participants provide the framework for the randomized comparison of the two parallel arms. |
| Participants at risk of HIV-1 acquisition | Contribute follow-up to the acquisition endpoint according to the prespecified event and censoring rules. |
| Participants who become HIV infected | Form the endpoint-defined population for viral load set point. |
This distinction illustrates a central principle in clinical-trial statistics: the analysis population is part of the estimand. An effect estimated across all randomized participants answers a different question from an effect estimated only among participants selected by a post-randomization outcome.
The acquisition endpoint is naturally tied to the randomized prevention comparison. The viral load endpoint is explicitly conditional on infection. Therefore, the two endpoints should not be interpreted as though they represented identical populations or identical causal questions.
10. Why Time-to-Event Analysis Is Useful Here
Suppose two randomized groups had the same number of HIV-1 acquisition events but substantially different timing of those events. A simple event proportion would not distinguish those patterns. Time-to-event analysis can, because it retains the temporal ordering of events and accounts for participants whose observed follow-up ends without an acquisition event.
The hazard describes the instantaneous event rate among participants who remain event-free immediately before time t. It is not the same as the cumulative probability of infection.
If a Cox model were used, a hazard ratio below 1 would indicate a lower estimated instantaneous acquisition rate in the vaccine group relative to placebo under the fitted model. It would not mean that the same percentage of individuals were prevented from infection, and it would not directly give an absolute reduction in cumulative infection probability.
The proportional-hazards assumption would also matter for a Cox-model interpretation. A single hazard ratio summarizes a relative event rate under the model; if the relative hazard changes materially over time, the single-number summary may not fully describe the underlying event-time patterns.
11. Why the Viral Load Endpoint Requires Separate Attention
Viral load set point is defined at approximately 3 months postdiagnosis, rather than throughout study follow-up. This gives the endpoint a fixed postdiagnosis assessment window, but it also means that the endpoint is only available for participants who become HIV infected.
Timing
The registered time frame is approximately 3 months postdiagnosis. The endpoint therefore concerns a defined period after HIV diagnosis rather than the entire follow-up period.
Measurement
The endpoint is HIV-1 RNA, a quantitative virologic measurement. Its statistical treatment is therefore different from the event indicator used for HIV-1 acquisition.
Eligibility for analysis
Only study participants who become HIV infected are included in the endpoint definition.
Interpretation
An estimated treatment difference in viral load set point would describe a virologic comparison among participants meeting the infection criterion, not a treatment effect across all 801 enrolled participants.
12. Limitations and Interpretation Issues
- No posted statistical analyses: The ClinicalTrials.gov record contains the registered primary endpoints but no posted statistical analyses or numerical endpoint results.
- Endpoint-specific populations: HIV-1 acquisition concerns the prevention cohort under follow-up, whereas viral load set point is explicitly restricted to study participants who become HIV infected.
- Conditioning on infection: Because infection occurs after randomization, restricting an analysis to participants who become infected requires more careful interpretation than the original randomized comparison.
- Censoring: Any time-to-event analysis of HIV-1 acquisition depends on prespecified rules for when participants are considered no longer observed or at risk.
- Time frame: The two primary endpoints use different temporal structures: acquisition is assessed throughout the study, while viral load set point is assessed at approximately 3 months postdiagnosis.
- Unspecified modeling details: The available registry information does not specify the statistical model, transformation, censoring rules, missing-data method, or inferential procedure used for the endpoints.
- Continuous-outcome distribution: Appropriate analysis of HIV-1 RNA depends on its observed distribution and the prespecified statistical framework; a single unadjusted mean comparison should not be assumed without examining those properties.
- Generalizability: The registered population is specifically HIV-uninfected South African adults, so applicability to populations with different eligibility characteristics should be considered separately.
13. Why This Trial Matters Statistically
HVTN 503 is a useful teaching example because its two primary endpoints illustrate how the same randomized trial can contain fundamentally different statistical questions. The first endpoint is an event occurring over time. The second is a quantitative measurement assessed only among participants who experience the event.
| Concept | How it appears in HVTN 503 |
|---|---|
| Randomization | The study uses randomized allocation between two parallel arms. |
| Prevention analysis | HIV-1 acquisition is the primary prevention endpoint. |
| Time-to-event analysis | HIV-1 acquisition can naturally be analyzed using event time and censoring. |
| Survival function | Event-free follow-up can be described as remaining free of HIV-1 acquisition over time. |
| Hazard ratio | A Cox-model hazard ratio is one possible relative measure for the acquisition endpoint when the model is appropriate. |
| Incidence rate | HIV-1 acquisition can also be described using events per accumulated person-time. |
| Continuous outcome | Viral load set point is a quantitative HIV-1 RNA endpoint. |
| Conditional analysis | Viral load set point is defined only among participants who become HIV infected. |
| Analysis population | The population for viral load set point differs from the population used to assess acquisition. |
| Estimands | The two endpoints represent distinct questions and should not be collapsed into a single treatment effect. |
14. A Deeper Statistical Reading of the Trial
Randomization answers the first causal question
For HIV-1 acquisition, randomization establishes the primary comparison before infection status is known. This is the cleanest statistical setting in the trial: participants are assigned to the vaccine or placebo arm, followed prospectively, and the occurrence and timing of infection can then be compared.
Infection changes the statistical question
Once attention shifts to viral load set point, the analysis is no longer performed across all randomized participants. Only participants who become infected are eligible for that endpoint. The analysis therefore describes virologic outcomes conditional on a post-randomization event.
This distinction is more than a technical detail. A treatment could theoretically influence both whether infection occurs and what happens after infection. Conditioning on infection can therefore alter the composition of the analyzed population. The resulting estimate should be interpreted as an association within the endpoint-defined infected population unless the statistical analysis plan provides a more specific causal framework.
Relative and absolute measures answer different questions
For HIV acquisition, a relative measure such as a hazard ratio can describe how the instantaneous acquisition rate compares between randomized groups. An absolute measure, such as a cumulative infection probability at a specified time, answers how many infections occur by that point. These are complementary rather than interchangeable summaries.
Statistical significance is not effect magnitude
If a formal comparison were reported, a p-value would address evidence against a specified null hypothesis under the statistical model. It would not by itself quantify the magnitude or practical importance of a treatment effect. Effect estimates and their confidence intervals provide the information needed to understand magnitude and precision.
The strongest interpretation comes from matching the analysis to the endpoint: use event-time methods for HIV-1 acquisition and an appropriate continuous-outcome framework for viral load set point, while recognizing that the latter is restricted to participants who become infected.
15. Registry Timeline
Study start
The ClinicalTrials.gov record lists 2007-01 as the study start date.
Primary completion
The ClinicalTrials.gov record lists 2012-08 as the primary completion date.
Study status
The registry lists the study as completed and identifies 801 participants as the enrollment total.
16. What the Registry Does and Does Not Establish Statistically
Established by the record
The study was randomized, used a parallel design, had two arms, enrolled 801 participants, and registered two primary endpoints with defined time frames.
Not reported in the record
The available ClinicalTrials.gov record does not post formal statistical analyses or numerical results for the two registered primary endpoints.
This distinction is important when reading a trial registry statistically. Registration establishes what outcomes were designated and how the study was structured. A completed registry entry without posted numerical analyses does not by itself provide an effect estimate, confidence interval, or p-value.
17. Sources
- ClinicalTrials.gov: HVTN 503 (NCT00413725).
Continue through the Clinical Biostats clinical-trial library
Clinical trial pages connect study design, endpoints, statistical reasoning, and interpretation across different therapeutic areas and development settings.
18. Record Summary
HVTN 503 is a randomized phase 2 prevention trial of a three-dose regimen of MRKAd5 HIV-1 Gag/Pol/Nef versus placebo in HIV-uninfected South African adults. Its statistical structure is particularly instructive because the two registered primary endpoints operate at different levels: acquisition of HIV-1 infection is an event occurring during follow-up, whereas viral load set point (HIV-1 RNA) is a quantitative postdiagnosis outcome assessed among participants who become HIV infected. The ClinicalTrials.gov record reports the trial design, enrollment, dates, intervention structure, and endpoint definitions, but does not post formal statistical analyses or numerical results for those primary endpoints.
The central statistical lesson is therefore about matching the estimand and analysis population to the endpoint. HIV-1 acquisition naturally calls for methods that respect event timing and censoring, while viral load set point requires an appropriate continuous-outcome analysis within the endpoint-defined infected population. Treating these endpoints as if they represented the same statistical question would obscure an important part of the trial's design.